Phase I Study of EOC237 in Patients With Advanced Solid Tumor

• Status: Not yet recruiting
• Trial end date: 2026-09-30
• Target enrollment: 0
• Participant gender: All

Summary

This research study is studying an investigational drug called EOC237 in Patients With Advanced Solid Tumor.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Yiteng Jingang Bio-pharmaceutical Technology Co., Ltd

Criteria

Inclusion Criteria:

• Advanced Solid Tumors for which standard curative or palliative measures do not exist or are no longer effective.

• Measurable lesion according to RECIST 1.1 evaluation criteria.

• Expected survival≥ 3 months.

• ECOG performance status 0-1.

• Good organ and marrow function.

Exclusion Criteria:

• Patients with a history of severe drug allergic reaction.

• Pregnant or lactating female subjects.

• Uncontrolled, significant intercurrent or recent illness.

• Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per electrocardiogram (ECG)

• Concomitant use of certain medications